COMMUNIQUÉS West-GlobeNewswire

Iolyx Therapeutics to Present at Multiple Upcoming Ophthalmology Conferences

12/03/2025 - 13:30

BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Iolyx Therapeutics, a clinical-stage biotechnology company focused on the development of therapeutics at the intersection of ocular inflammation and autoimmunity, [...]

Digicann Ventures Announces Agreement to Extend Maturity Date for Convertible Debentures

11/03/2025 - 22:00

VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. (“Digicann” or the “Company”) (CSE: DCNN) (OTCPK: AGFAD), a company focused on opportunities within and outside of the cannabis [...]

Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades

11/03/2025 - 21:40

AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer : The first Porous PEEK™ [...]

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

11/03/2025 - 21:30

Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic (Privosegtor, OCS- [...]

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

11/03/2025 - 21:30

ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic [...]

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11/03/2025 - 21:28

BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock [...]

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

11/03/2025 - 21:27

Raanana, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, [...]

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results

11/03/2025 - 21:15

Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose [...]

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

11/03/2025 - 21:05

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host conference call and [...]

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

11/03/2025 - 21:05

ROCKVILLE, MD, March 11, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization [...]

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

11/03/2025 - 21:05

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL [...]

Sanara MedTech to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

11/03/2025 - 21:05

FORT WORTH, TX, March 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to [...]

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

11/03/2025 - 21:05

ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024

11/03/2025 - 21:05

Increased Product Sales to $133 Million in 2024 Generated Pre-tax Operating Income and Net Income of $70 Million and $59 Million, Respectively, in 2024 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, [...]

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

11/03/2025 - 21:05

– Company generated quarterly sequential growth in YCANTH ® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than [...]

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

11/03/2025 - 21:01

Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially registrational [...]

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

11/03/2025 - 21:01

- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in [...]

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

11/03/2025 - 21:01

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; [...]

Tilray Medical lance Tilray Craft et introduit des variétés génétiques à forte teneur en THC et en terpènes sur le marché allemand du cannabis thérapeutique

11/03/2025 - 19:12

NEUMÜNSTER, Allemagne, 11 mars 2025 (GLOBE NEWSWIRE) -- Tilray Medical, (« Tilray »), une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique qui permet aux [...]